| The Fleet · Flagship Systems
Plate IV / IX | Full Register →
Plate IV — Xzom
Med Device & Diagnostics Diagnostics · Biotech · Point-of-Care
Designation

Xzom

Early-enough detection — exosome diagnostics from a drop of blood.
ASSAY ARRAY · 5 × 3 + SIGNAL DETECTION TRACE
Fig. 4 — Exosome isolation & detection traceSan Diego, CA
Classification
SectorMed Device · Diagnostics
SystemExosome diagnostic platform
OriginSan Diego, CA
PositionSeed
The Mission

The earliest signal of disease is often the hardest to read. Xzōm harnesses extracellular vesicles (exosomes) — biology's continuously-secreted messengers — using a proprietary Alternating Current Electrokinetics (ACE) platform to isolate and analyze them from under 100 microliters of blood in less than 30 minutes. The pioneering target: early detection of pancreatic cancer, with a pipeline across oncology to follow.

Signal — Public Milestones
Proprietary ACE platform isolates exosomes from <100µL of blood in under 30 minutes
Lead application: early pancreatic cancer detection, with a broader oncology pipeline
Near-patient design built for low-cost, accessible early detection
The Fleet — Nine Flagship Systems
PL. I
Natilus
PL. II
Seasats
PL. III
Omnitron
PL. IV
Xzom
PL. V
BlueNalu
PL. VI
Firestorm
PL. VII
Eventship
PL. VIII
Cabana
PL. IX
Bear Club